White House warns Pfizer Covid-19 pill will not be widely available for months – FT
|
The White House dims optimism over the Omicron cure after the US Food and Drug Administration (FDA) approved a pill from Pfizer to treat Covid-19.
“The White House has warned it will take more than six months to fulfill its initial order for Pfizer’s antiviral Covid-19 pill, as officials damped speculation the drug could immediately turn the tables on the pandemic,” said the Financial Times (FT)
Key quotes (from FT)
The US drugs regulator on Wednesday gave emergency authorization for the pill, called Paxlovid, to be used on people aged 12 and over with mild or moderate Covid-19 who are at risk of more severe symptoms.
But senior health advisers to President Joe Biden quickly warned that it would take months for the company to make and distribute all 10m treatment courses already on order.
Pfizer has said its pill cuts the risk of hospitalisation or death in Covid-19 patients by 89 percent.
It is likely to be especially important in the coming months because early lab tests show it continues to work against the fast-spreading Omicron variant, unlike some of the monoclonal antibody treatments already available.
FX reaction
Given the latest risk-on mood mainly driven by hopes of overcoming the South African covid variant, dubbed as Omicron, the news negatively affects the sentiment and should weigh on the recent gainers, namely Antipodeans and commodities.
Read: AUD/USD: Well-set for 0.7300 on firmer sentiment, US Durable Goods Orders, PCE Inflation eyed
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.
